Printer Friendly

CHRONIMED REPORTS NINE MONTH AND THIRD QUARTER RESULTS; FIRST REPORT SINCE INITIAL PUBLIC OFFERING

 CHRONIMED REPORTS NINE MONTH AND THIRD QUARTER RESULTS;
 FIRST REPORT SINCE INITIAL PUBLIC OFFERING
 MINNEAPOLIS, May 5 /PRNewswire/ -- Chronimed Inc. (NASDAQ: CHMD) today announced its third quarter and nine months results, the first reported financial results since its initial public offering on March 20, 1992. Chronimed's fiscal year ends June 30, 1992.
 For the nine months ended March 31, 1992, Chronimed reported net income of $221,751, up from a loss of $98,954 posted for the same period in 1991. Income per share was also up, to $.05 for the nine month period compared to a $.03 loss for the same period in 1991. Revenue for this nine month period was $14.18 million, up 69 percent from $8.41 million for the 1991 period.
 As anticipated, the net loss for the third quarter of 1992 was $84,048, compared to a net loss of $129,813 in the third quarter of 1991. Revenue for the quarter was up 58 percent from $2.80 million in 1991 to $4.42 million this year. Quarterly weighted average common and equivalent shares outstanding increased from 3.45 million a year earlier to 3.89 million this quarter.
 Historically, the company has experienced a decrease in revenues during its third fiscal quarter. This seasonality of revenues is the result of individuals with diabetes accelerating their purchases of medical products before new insurance deductible calculations begin, which is generally on Jan. 1, the beginning of the calendar year.
 According to Chronimed President and CEO Maurice R. Taylor, the company's operating results will become less seasonal as sales of transplant and other medical products become a more significant part of the company's total revenues. All areas of the company are growing, with the transplant segment of the business growing more rapidly than the diabetes segment.
 "Chronimed is well positioned for future growth as we begin to expand our services to meet the special needs of persons with other chronic conditions," said Taylor.
 Chronimed Inc. is a Minnesota-based distributor of prescription drugs, medical and nutritional products and proprietary educational materials by mail order to people with chronic health conditions.
 -0- 5/5/92
 /CONTACT: Maurice R. Taylor II of Chronimed, 612-541-0239/
 (CHMD) CO: Chronimed Inc. ST: Minnesota IN: SU: ERN


GK -- NY098 -- 6803 05/05/92 17:37 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:384
Previous Article:TREADCO, INC. ANNOUNCES 1992 SECOND QUARTER CASH DIVIDEND
Next Article:KERR-MCGEE DECLARES QUARTERLY DIVIDEND


Related Articles
CHRONIMED ANNOUNCES FIRST QUARTER RESULTS
CHRONIMED ANNOUNCES SIX MONTH AND SECOND QUARTER RESULTS
CHRONIMED ANNOUNCES NINE MONTH AND THIRD QUARTER RESULTS
CHRONIMED ANNOUNCES NINE MONTH AND THIRD QUARTER RESULTS
CHRONIMED ANNOUNCES THIRD-QUARTER AND NINE-MONTH RESULTS
CHRONIMED ANNOUNCES THIRD QUARTER AND NINE MONTH RESULTS
Chronimed Announces First Quarter Fiscal 1999 Results.
Chronimed Lowers Second Half Earnings Outlook; Management Cites Short Term Timing and Performance Issues.
Chronimed Reports Fiscal 2000 Second Quarter Results.
Chronimed Reports Fiscal 2000 Third Quarter Results; Operating Income For Combined Company Hits $0.10 per Share Before Non-Recurring Items.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters